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Brief Communication
Tonic Facilitation of Glutamate Release by Presynaptic
NR2B-Containing NMDA Receptors Is Increased in the
Entorhinal Cortex of Chronically Epileptic Rats
Jian Yang,1 Gavin L. Woodhall,2, and Roland S. G. Jones1
1Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, United Kingdom, and 2The Molecular Biosciences Research Group, School
of Life and Health Sciences, Aston University, Birmingham B4 7ET, United Kingdom
Wehave shownpreviously thatwhenpostsynapticNMDAreceptors are blocked, the frequency, but not amplitude, of spontaneousEPSCs
(sEPSCs) at synapses in the entorhinal cortex is reducedbyNMDAreceptor antagonists, demonstrating that glutamate release is tonically
facilitated by presynaptic NMDA autoreceptors. In the present study, we recorded sEPSCs using whole-cell voltage clamp in neurons in
layer V in slices of the rat entorhinal cortex. Using specific antagonists for NR2A [(R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-
1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid] and NR2B [(R,S)--(4-hydroxyphenyl)--methyl-4-(phenylmethyl)-
1-piperidinepropanol hydrochloride (Ro 25-6981)] subunit-containing receptors, we confirmed that in slices from juvenile rats (4–6
weeks of age), the autoreceptor is predominantly of the NR1–NR2B subtype. In older (4–6 months of age) control animals, the effect of
the NR2B antagonist was less marked, suggesting a decline in autoreceptor function with development. In slices from rats (aged 4–6
months) exhibiting spontaneous recurrent seizures induced with a lithium-pilocarpine protocol, Ro 25-6981 again robustly reduced
sEPSC frequency. The effect was equal to or greater than that seen in the juvenile slices andmuchmore pronounced than that seen in the
age-matched control animals. In all three groups, the NR2A antagonist was without effect on sEPSCs. These results suggest that there is
a developmental decrease inNMDAautoreceptor function,which is reversed in a chronic epileptic condition. The enhanced autoreceptor
function may contribute to seizure susceptibility and epileptogenesis in temporal lobe structures.
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Introduction
The release of glutamate at cortical synapses is controlled by an
array of presynaptic receptors, providing a powerful means of
dynamically regulating excitatory transmission at both the net-
work level and in a synapse-delimited way. For example, hetero-
receptor control of release is effected by GABAB, adenosine, and
muscarinic receptors, whereas both ionotropic (NMDA, kainate)
and metabotropic glutamate receptors act as autoreceptors.
Work in this laboratory has focused on presynaptic receptor con-
trol of glutamate release at synapses in the rat entorhinal cortex
(EC). We provided one of the earliest physiological demonstra-
tions that NMDA autoreceptors tonically facilitate glutamate re-
lease at excitatory synapses (Berretta and Jones, 1996). Subse-
quently, we have shown that these receptors are likely to be
predominantly of the NR1–NR2B subtype and that they mediate
frequency-dependent facilitation of glutamate transmission,
probably by increasing intraterminal Ca via the receptor iono-
phore (Woodhall et al., 2001). A number of other studies have
also demonstrated functional presynaptic NMDA receptors in
different brain areas (Breukel et al., 1998; Hamada et al., 1998;
Cochilla andAlford, 1999; Glitsch andMarty, 1999; Casado et al.,
2000; Dalby and Mody, 2003; Sjostrom et al., 2003; Duguid and
Smart, 2004; Samson and Pare, 2005).
There is evidence to suggest that NMDA receptor function is
altered in chronically epileptic states. In particular, an increase in
receptor number and/or function has often been observed (Dalby
andMody, 2001; Avanzini and Franceschetti, 2003; Morimoto et
al., 2004). These studies have concentrated on NMDA receptors
at postsynaptic sites, and we do not know yet whether chronic
epileptic conditions are associated with adaptive changes in
NMDA autoreceptors or heteroreceptors. However, a recent
study showed that the density of ()-5-methyl-10,11-dihydro-
5H-dibenzo [a,d] cyclohepten-5,10-imine maleate (MK-801)
binding sites is increased in synaptosomes isolated from temporal
cortical tissue from epileptic patients (Steffens et al., 2005), sug-
gesting that presynapticNMDA functionmay be increased. In the
present study, we examined the functional physiological effect of
NMDA autoreceptors in EC slices from chronically epileptic rats.
We found that facilitation of glutamate release by theNR2B subtype
of receptor declined with age in normal animals but became func-
tionally upregulated in the chronic epileptic condition.
Materials andMethods
Combined entorhinal–hippocampal slices were prepared from male
Wistar rats, as described previously (Jones and Heinemann, 1988). Rats
Received Oct. 17, 2005; revised Nov. 18, 2005; accepted Nov. 19, 2005.
We thank the Epilepsy Research Foundation and the Wellcome Trust for financial support and the University of
Bristol for a postgraduate research scholarship to J.Y.
Correspondence should be addressed to Gavin L. Woodhall, Department of Pharmacy and Pharmacology, Uni-
versity of Bath, Claverton Down, Bath BA2 7AY, UK. E-mail: g.l.woodhall@aston.ac.uk.
DOI:10.1523/JNEUROSCI.4413-05.2006
Copyright © 2006 Society for Neuroscience 0270-6474/06/260406-05$15.00/0
406 • The Journal of Neuroscience, January 11, 2006 • 26(2):406–410
were anesthetized with an intramuscular injection of ketamine (120 mg/
kg) plus xylazine (8 mg/kg) and decapitated. The brain was removed
rapidly and immersed in oxygenated artificial CSF (ACSF) chilled to 4°C.
Slices (350 m) were cut using a Vibroslice and stored in ACSF bubbled
with 95% O2/5% CO2 at room temperature. After recovery for at least
1 h, individual slices were transferred to a recording chamber mounted
on the stage of a Zeiss (Oberkochen, Germany) Axioskop FSmicroscope.
The chamber was perfused (2ml/min) with oxygenated ACSF, pH 7.4, at
30–32°C. The ACSF contained the following (inmM): 126NaCl, 2.5 KCl,
1.25 NaH2PO4, 24 NaHCO3, 2 MgSO4, 2.5 CaCl2, and 10 D-glucose.
Neurons were visualized using differential interference contrast optics
and an infrared video camera.
Patch pipettes (1–4 M) were pulled from borosilicate glass on a
Flaming/Brown microelectrode puller. Pipettes were filled with a Cs-
gluconate-based solution containing the following (in mM): 100
D-gluconate, 40 HEPES, 1N-ethyl bromide quaternary salt, 0.6 EGTA, 4
NaCl, 5 MgCl2, 1 tetraethylammonium-Cl, 4 ATP-Na, 0.3 GTP-Na, and
1MK-801. The solutionwas adjusted to 275mOsmby dilution and set to
pH 7.3 with CsOH. Whole-cell voltage-clamp recordings were made
from neurons in layer V of the medial division of the EC, using an
Axopatch 200B amplifier. Using this pipette solution and with mem-
brane potential voltage clamped at60 mV, neurons displayed sponta-
neous EPSCs (sEPSCs). The open channel blockerMK-801 was included
in the patch pipette to block postsynaptic NMDA receptor in the re-
corded neuron (Berretta and Jones, 1996). To facilitate this blockade,
neuronswere depolarized to10mV for 10 s at intervals during a 10min
period after breakthrough to whole-cell access. Thus, it should be
stressed that all of the recordings presented here were conducted with
postsynaptic NMDA receptors blocked, and under these experimental
conditions, EPSCs were mediated by spontaneous release of glutamate
acting at AMPA/kainate receptors. Series resistance compensation was
not used, but access resistance (10–30 M) was monitored at regular
intervals throughout each recording, and cells were discarded from anal-
ysis if it changed by more than 10%. Liquid junction potentials were
estimated using the calculator of pClamp 8 software and compensated
for in the holding potentials.
Data were recorded to computer hard disk using Axoscope software.
Minianalysis (Synaptosoft, Decatur, GA) was used for analysis of sEPSCs
off-line. sEPSCs were detected automatically using a threshold-crossing
algorithm. Two hundred sEPSCs were sampled during a continuous re-
cording period for each neuron under each condition. To compare
pooled data under control and drug conditions, we determined median
values for interevent interval (IEI) and amplitude for events in each cell
and calculated themeanmedian values for the population, using a paired
t test for statistical comparison. All error values stated in the text refer to
SEM.We also assessed the significance of shifts in cumulative probability
distributions of IEI using the nonparametric Kolmogorov–Smirnoff
(KS) test.
Previously, we used the relatively selective antagonist ifenprodil to
assess whether presynaptic NMDA receptors contained the NR2B sub-
unit (Woodhall et al., 2001). In the present study, we examined the effect
of a more specific antagonist at NR2B receptors, (R,S)--(4-
hydroxyphenyl)--methyl-4-(phenylmethyl)-1-piperidinepropanol hy-
drochloride (Ro 25-6981; Tocris Cookson, Bristol, UK) (Fischer et al.,
1997). This was compared with the specific NR2A antagonist (R)-[(S)-
1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquino-
xalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077; a kind gift from
Dr. Yves Auberson, Novartis Pharmaceuticals, Basel, Switzerland)
(Auberson et al., 2002).
Initial experiments to determine the effects of the NR2A- and NR2B-
selective agonists were performed in slices taken from juvenile animals
(4–6 weeks of age). In studies comparing chronically epileptic rats with
age-matched controls, the animals were aged 4–6 months at the time of
electrophysiological experiments.
Rats were rendered chronically epileptic using a modified version of
the pilocarpine model described by Glien et al. (2001). They were pre-
treated with LiCl (300 mg/kg, i.p.). Twenty-four hours later, they re-
ceived -methyl scopolamine (1 mg/kg, i.p.) to block the peripheral
cholinergic effects of pilocarpine, and 15 min later received pilocarpine,
administered in very lowdoses (5mg/kg), repeated as necessary at 30min
intervals until an acute status epilepticus (SE) was induced. After induc-
tion of SE, animals were administered the central muscle relaxant xyla-
zine (4 mg/kg, i.m.), which reduced the severity of clonic contractions
without preventing electrical seizure activity. After 2 h in SE, seizures
were terminated with diazepam (10 mg/kg, i.p.) and animals monitored
to full recovery of consciousness. When necessary, they were given nor-
mal saline subcutaneously on the day with SE and on the following day
for rehydration. Using this modified approach, we achieved a mortality
rate of 5–10% and development of spontaneous recurrent seizures in
100%of animals. Age-matched control animals received the initial injec-
tion of LiCl but nothing else. This procedure was performed under a UK
Home Office project license (PPL30/1877).
After the acute SE, animals developed evidence of epileptic seizure
activity during a latent period of 6–10 weeks. This included the appear-
ance of occasional head twitches, wet dog shakes, forepaw clonus, orofa-
cial movements, and whole-body jerks. Eventually, all animals began to
display spontaneous recurrent seizures, characterized by rearing plus loss
of balance and accompanied by generalized clonic seizures. Animals were
used for electrophysiology 2–4 weeks after first developing spontaneous
recurrent seizures.
Results
Differences in sEPSCs between groups
There were some differences in sEPSC characteristics in the three
groups that were evident even in the relatively small sample of
neurons reported on here. These differences, and their signifi-
cance, will be described in detail for a much larger population of
neurons in a report being prepared for submission (G. Ayman,
G. L. Woodhall, and R. S. G. Jones, unpublished observations).
Although there are quantitative differences in the wider popula-
tion, qualitatively the differences are the same. sEPSC amplitudes
were slightly larger in the cells from epileptic animals compared
with both age-matched controls and juvenile animals. Rise and
decay times were slower in older animals compared with younger
but are very similar in both groups (epileptic and controls). The
biggest difference was in the frequency of events, which was sim-
ilar in young animals (3.4  0.6 Hz; n  6) and old controls
(2.7 1.1 Hz; n 6) but higher andmore variable in slices from
epileptic animals (12 8.4 Hz; n 7).
NR2B but not NR2A receptor blockade depresses
sEPSC frequency
In juvenile animals, we have shown previously that the nonspe-
cific antagonist 2-AP-5 and the relatively selective NR2B antago-
nist ifenprodil both decrease the frequency of sEPSCs in EC neu-
rons by blocking tonically active presynaptic NMDA receptors
(Berretta and Jones, 1996;Woodhall et al., 2001).We now report
a similar effect with the highly specific NR2B antagonist Ro 25-
6981. In six cells, the mean IEI under control conditions was
334.6 49.2 ms with ameanmedian of 183.8 38.2 ms. During
perfusion with Ro 25-6981 (1 M), the mean IEI increased to
600.0 136.6 ms with a mean median of 360.6 75.9 ms ( p
0.05). Mean median amplitudes were unaltered (10.7  0.8 vs
10.4  0.6 pA). Rise and decay times of sEPSCs were also unal-
tered (data not shown). Figure 1A shows an example of one
neuron in which Ro 25-6981 clearly decreased the frequency of
sEPSCs. The cumulative probability distributions for IEI for
pooled data from six neurons in Figure 1B shows that in the
presence of the drug the distribution is shifted to the right (KS,
p 0.01), reflecting the decreased frequency of sEPSCs.
In contrast to the effect of the NR2B antagonist, the NR2A
antagonist NVP-AAM077 (3 M) had no significant effect on
sEPSCs in five neurons in slices from young animals. Thus, mean
median IEI was 305.3  68.4 ms in control conditions. If any-
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thing, there was a slight increase in frequency of sEPSCs in the
presence of the drug, but themeanmedian IEI (279.5 52.3ms)
was not significantly different. Likewise,meanmedian amplitude
(11.5  2.8 vs 11.3  2.0 pA) rise and decay times (data not
shown) were also unaffected. Cumulative probability distribu-
tions of IEI for pooled data in the presence and absence of NVP-
AAM077 are shown in Figure 1C. KS analysis showed that the
slight shift to the left was not significant.
NR2B receptor blockade is more effective in young versus
adult rats
In adult animals, the effect of Ro 25-6981 on sEPSC frequency
was considerably less robust than in the young animals (Fig. 1D).
Thus, the mean IEI in control conditions was 543.7  77.4 ms
(n 6) with a mean median of 367.0 74.8 ms. In the presence
of Ro 25-6981, the corresponding values were 606.9  83.8 and
451.3  69.4 ms. Neither change was significant when assessed
with a paired t test. However, KS analysis of the cumulative prob-
ability distributions of pooled IEIs (Fig. 1E) showed that the
small rightward shift in the presence of the antagonist was signif-
icant ( p 0.05). Concurrently, there was no significant change
in amplitude (meanmedian, 9.9 0.5 vs 9.9 0.9 pA) or rise and
decay times (data not shown). Thus, the influence of presynaptic
NMDA receptors on glutamate release in adult control animals
was reduced compared with that seen in juveniles. On average,
the frequency of sEPSCs decreased by40% in neurons in young
slices but only 15% in the adult group. The reduction in effect of
the NR2B antagonist was not accompanied by an increased effect
of blocking NR2A receptors in slices (n 4) from older animals.
Thus, there was no significant effect of NVP-AAM077 on mean
median IEI (414.3 50.5 vs 362 31.3 ms) or amplitude (8.8
0.9 vs 8.4 0.9 pA) of sEPSCs, although again, there was a slight
increase in overall frequency in the presence of the drug. Pooled
data showing the effect of NVP-AAM077 on IEI can be seen in
Figure 1F.
Increased effect of presynaptic NR2B receptors in
epileptic rats
As mentioned above, the frequency of sEPSCs in neurons from
epileptic animals was higher than that in controls and quite vari-
able fromneuron to neuron. Thus, themean IEI in seven neurons
was 222.3 104.0 ms with a mean median of 145 61.0 ms. In
the presence of Ro 25-6981, these values increased to 337.4 
207.7 and 341 131.8 ms, respectively. Thus, the NR2B antago-
nist, on average, induced a reduction in frequency of55%. The
reduction in one neuron is shown in Figure 2A. Despite the vari-
ability, the difference in IEI was significantly different when as-
sessed either by a paired t test ( p 0.05) or by KS analysis ( p
0.001) of cumulative probability distributions (Fig. 2B). The de-
creased frequency was not accompanied by a significant change
in amplitude. In the control situation, the mean amplitude was
15.4 1.3 pA (with ameanmedian of 12.7 0.9) comparedwith
14.3 1.1 pA (12.0 1.0 pA) in the presence of the drug.Neither
rise time nor decay was altered (data not shown).
There was no evidence for change in subunit composition of
the presynaptic receptors in the epileptic rats. Thus, the powerful
effect of the NR2B antagonist in the epileptic animals was not
matched by the NR2A receptor blocker (Fig. 2C,D). Thus, as in
the neurons in juvenile and age-matched older control groups,
NVP-NAM077 had no discernible effect on mean median IEI
(220 70 vs 239 83.7 ms) or amplitude (10.6 1.1 vs 10.3
1.6 pA) of sEPSCs in five neurons recorded in slices fromepileptic
animals.
Figure1. PresynapticNR2B-containing receptors facilitateglutamate releasemore in young
animals than in old. A, Voltage-clamp recordings of sEPSCs in a layer V neuron in a slice from a
4-week-old animal. With postsynaptic receptors blocked by intracellular MK-801, blockade of
NR2B receptors decreases the frequency of sEPSCs. B, Pooled data for an interevent interval
from six neurons shows a shift to the right of the cumulative probability distribution in the
presence of Ro 25-6981 compared with the control. C, In contrast, in the presence of the NR2A
antagonist NVP-AAM077 (1 M), there was a small, nonsignificant shift to the right of the
cumulative probability distribution, indicating that these receptors were not controlling gluta-
mate release in juvenile animals. D, Voltage-clamp recordings from a neuron in a slice from a
5-month-old rat. The NR2B antagonist reduced sEPSC frequency, but the effect was much less
robust than in the juvenile animal. This is reflected in the pooled data for an interevent interval
in adult control neurons shown in E. F, Pooled data for the effects of NVP-AAM077 in adult
neurons. Again there was a small, nonsignificant increase in frequency. Ro, Ro 25-6981; c,
control; NVP, NVP-AAM077.
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Discussion
We have shown previously that presynaptic NMDA receptors
tonically facilitate glutamate release at synapses in the EC (Ber-
retta and Jones, 1996; Woodhall et al., 2001) and suggested that
the autoreceptor is likely to be predominantly of the NR1–NR2B
subtype. The latter observation was strengthened in the current
study, because the frequency of sEPSCs at EC synapses was re-
duced by the NR2B-selective antagonist Ro 25-6981 but unal-
tered by the NR2A antagonist NVP-AAM077. Investigations of
postsynaptic NMDA receptors have shown that cortical expres-
sion of NR2B receptors is present at birth, rises through early
development [up to around postnatal day 20 (P20)], and then
decreases slightly or is sustained throughout adulthood. NR2A
expression is almost undetectable at P0 but increases rapidly up
to P20–P28 and then also remains stable throughout adulthood
(Sheng et al., 1994; Zhong et al., 1995; Wenzel et al., 1997; Liu et
al., 2004). A similar profile of changes has been demonstrated in
human hippocampal formation (Law et al., 2003). Interestingly,
the latter study found the biggest decline in NR2B expression
between neonates and adult to occur in the subiculum and EC
and the largest change in NR2A:NR2B ratio in the EC.
These changes in subunit expression have led to the sugges-
tion that there is a developmental switch from NR2B-containing
receptors to NR2A at glutamate synapses, with important conse-
quences for postsynaptic responsiveness and synaptic plasticity
(Quinlan et al., 1999; Liu et al., 2004). Our studies show a devel-
opmental change in the tonic facilitation of glutamate release by
NMDA autoreceptors, with a reduced effectiveness in 4- to
5-month-old animals. This is unlikely to be the result of a switch
from NR2B- to NR2A-containing receptors at presynaptic sites,
because the specific NR2A antagonist was ineffective in reducing
glutamate release in either young or old animals. It is possible that
the loss of the autoreceptor function in the older animals may
reflect a simple loss of NR2B receptors from presynaptic sites, or
it could also reflect displacement of the NR2B receptors to sites at
which they may be relatively inaccessible to ambient glutamate.
Certainly, at postsynaptic sites, there appears to be a develop-
mental shift of the NR2B receptors to extrasynaptic locations
(Tovar and Westbrook, 1999; Liu et al., 2004), with an increased
contribution from subsynaptic NR2A receptors. However, it
would not appear that the presynaptic receptors switch to NR2A
in the adult, because the antagonist for the latter did not become
effective in these animals. Nevertheless, our data do suggest that
NR2B-containing autoreceptors may play a role in development
at excitatory synapses in the EC.
The reduced autoreceptor function in the older animals was
reversed in animals exhibiting chronic recurrent seizures. Thus,
blockade of NR2B receptors in slices from these animals resulted
in a reduction in sEPSC frequency that wasmore robust than that
seen in the juvenile age group. Again, NVP-AAM077 had no
effect. There is a substantial literature on changes in NMDA re-
ceptors associated with the development and maintenance of
cortical seizures, much of it suggesting an enhanced activation,
function, or expression of the receptors (Dalby and Mody, 2001;
Avanzini and Franceschetti, 2003; Morimoto et al., 2004). None
of the studies published to date have shown that changes in
NMDA receptor function apply to presynaptic sites. However, a
recent investigation has shown an increased Bmax of MK-801
binding, with no change in Kd, in synaptosomes prepared from
temporal cortex resected during surgery for epilepsy, suggesting
an increased density of presynaptic NMDA receptors with no
change in affinity (Steffens et al., 2005). There is increasing evi-
dence for enhanced expression of the NR2B-containing receptor
in both human epilepsy and animal models (Al-Ghoul et al.,
1997;Mathern et al., 1999; DeFazio andHablitz, 2000; Ying et al.,
2004). Such studies do not distinguish between presynaptic and
postsynaptic receptors, so it is possible that an increased expres-
sion of presynaptic NR2B-containing receptors may arise in epi-
leptic conditions. Our data support this possibility. However, we
cannot say whether the increased autoreceptor function reflects
an increased density of receptors on the terminals. Other possi-
bilities include a redistribution of receptors to sites more acces-
sible to ambient glutamate or altered properties or composition
of existing receptors.
We cannot say at present whether the change in autoreceptor
function in the EC is causally or casually related to epileptogen-
esis. It is interesting that dysplastic neocortical tissue resected
from patients with epilepsy shows enhanced NR2B binding, an
increased severity of epileptiform discharges provoked by lower-
ing extracellular Mg2, and an increased sensitivity of such dis-
charges to the NR2B antagonist ifenprodil (Moddel et al., 2005).
An increase in sensitivity of bicuculline-induced epileptiform ac-
Figure 2. Presynaptic NR2B receptors strongly facilitate glutamate release in epileptic ani-
mals.A,B, Voltage-clamp recordings showa robust decrease in sEPSC frequency in thepresence
of the NR2B antagonist in a neuron recorded in a slice from a 5-month-old epileptic rat, which
contrasts with its weak effect in age-matched control animals (Fig. 1D, E) but compares favor-
ably with the juvenile animals (Fig. 1A,B). C, D, The NR2B antagonist failed to alter sEPSC
frequency in epileptic animals, as in young and age-matched control animals. Ro, Ro 25-6981;
c, control; NVP, NVP-AAM077.
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tivity was seen in slices from rats with freeze lesion-induced cor-
tical dysplasia (DeFazio and Hablitz, 2000). Such effects could
reflect a contribution from increased NMDA autoreceptor func-
tion. It will be interesting to conduct similar experiments in EC
slices from control and epileptic rats, although it should be
stressed that such studies cannot discriminate between blockade
of receptors at presynaptic and postsynaptic sites.
Despite the fact that we cannot yet provide a functional link
between increased presynaptic NMDA autoreceptors and epilep-
togenesis, the enhanced level of background glutamate release is
certainly partly attributable to the increased autoreceptor func-
tion, and the enhanced background excitation will contribute to
elevated network excitability. It is interesting that the autorecep-
tor function appears to be diminished in normal adult animals
but is restored in the epileptic adults, essentially recapitulating an
earlier phase of development. There is evidence for recapitulation
of other aspects of cortical synaptic transmission in temporal lobe
epilepsy (e.g., re-emergence of excitatory actions of GABA)
(Cohen et al., 2003; Cossart et al., 2005), and it has been suggested
that the condition reflects a “pathological replay of developmen-
tal mechanisms” (Cohen et al., 2003). Thus, properties of cortical
networks in epilepsy may bear resemblance to those during early
development, a stage of heightened susceptibility to epileptogen-
esis (Holmes et al., 2002).
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